Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. (Q41752617)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Georgina V. Long

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Alexander M Menzies

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Peter Johansson

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Richard F. Kefford

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Helen Rizos

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

9

John F Thompson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

8

Varsha Tembe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

4

Gulietta M Pupo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

10

Robyn P Saw

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

5

Matteo S Carlino

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

2

Carina Fung

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

6

Jessica Hyman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

11

Julie Howle

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

7

Hamideh Shahheydari

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Nicholas K Hayward

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

language of work or name

English

0 references

publication date

2 December 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

published in

Nature Communications

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

5694

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/ncomms6694

23 February 2020

exact match

0 references

cites work

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

A landscape of driver mutations in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

A novel AKT3 mutation in melanoma tumours and cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Transforming mutations of RAC guanosine triphosphatases in human cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Mutations associated with familial melanoma impair p16INK4 function.

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

IDH1 and IDH2 mutations in gliomas

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Patterns of somatic mutation in human cancer genomes

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

MEK1 and MEK2, different regulators of the G1/S transition.

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Reconstitution of mitogen-activated protein kinase phosphorylation cascades in bacteria. Efficient synthesis of active protein kinases

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Fast and accurate short read alignment with Burrows-Wheeler transform

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

A framework for variation discovery and genotyping using next-generation DNA sequencing data

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

The Sequence Alignment/Map format and SAMtools

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

A third-generation lentivirus vector with a conditional packaging system

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors.

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6694

7 January 2021

Identifiers

DOI

10.1038/NCOMMS6694

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452114%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

0 references

1 reference